文献速递肺血管病与心包/心肌炎

新诊断肺动脉高压初始三联与双联口服治疗的比较

Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

TRITON为多中心双盲随机3b期研究,在新诊断未治肺动脉高压患者中比较初始三联(马西替坦+他达拉非+司来帕格)与双联(马西替坦+他达拉非+安慰剂)口服治疗。26周时两组肺血管阻力分别降低54%和52%,组间无显著差异(主要终点未达);探索性分析提示三联治疗可能降低疾病进展风险。

要点

  • 初始三联与双联口服治疗均显著降低26周肺血管阻力,组间无差异。
  • 探索性分析显示三联治疗疾病进展风险有降低趋势(HR 0.59,95%CI 0.32-1.09)。
  • 三联组常见不良事件为头痛、腹泻和恶心。

核心结论

  • 新诊断PAH患者中,初始三联与双联口服治疗均大幅降低26周PVR,组间无显著差异,主要终点未达。
  • 探索性分析提示初始三联相比双联可能改善长期结局。

研究设计与样本

  • TRITON为多中心、双盲、随机3b期研究(NCT02558231),纳入新诊断未治PAH患者。
  • 患者随机接受初始三联(马西替坦、他达拉非、司来帕格,n=123)或初始双联(马西替坦、他达拉非、安慰剂,n=124)口服治疗。
  • 主要终点为第26周肺血管阻力(PVR)变化,疗效评估至最后一位随机患者完成第26周。

主要发现

  • 第26周时,三联组和双联组PVR分别较基线降低54%和52%,组间几何均值比为0.96(95%CI 0.86-1.07,P=0.42)。
  • 6分钟步行距离和N末端脑钠肽前体至第26周均有改善,组间无差异。
  • 至主要观察期结束,三联组疾病进展风险相比双联组降低(HR 0.59,95%CI 0.32-1.09)。
  • 三联组最常见不良事件包括头痛、腹泻和恶心;主要观察期结束时,三联组死亡2例,双联组死亡9例。

临床怎么用

  • 对于新诊断PAH患者,初始双联口服治疗(马西替坦+他达拉非)可显著降低PVR,为主要终点未达的三联方案提供对照参考。
  • 初始三联口服治疗(加用司来帕格)虽未显著改善主要终点,但探索性分析提示可能降低长期疾病进展风险,需权衡不良反应。

局限性

  • 主要终点未达到,三联与双联的疗效差异未获统计学证实。
  • 疾病进展风险降低为探索性分析结果,置信区间包含1,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In pulmonary arterial hypertension (PAH), there are no data comparing initial triple oral therapy with initial double oral therapy. OBJECTIVES: TRITON (The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension; NCT02558231), a multicenter, double-blind, randomized phase 3b study, evaluated initial triple (macitentan, tadalafil, and selexipag) versus initial double (macitentan, tadalafil, and placebo) oral therapy in newly diagnosed, treatment-naive patients with PAH. METHODS: Efficacy was assessed until the last patient randomized completed week 26 (end of main observation period). The primary endpoint was change in pulmonary vascular resistance (PVR) at week 26. RESULTS: Patients were assigned to initial triple (n = 123) or initial double therapy (n = 124). At week 26, both treatment strategies reduced PVR compared with baseline (by 54% and 52%), with no significant difference between groups (ratio of geometric means: 0.96; 95% confidence interval: 0.86-1.07; P = 0.42). Six-minute walk distance and N-terminal pro-brain natriuretic peptide improved by week 26, with no difference between groups. Risk for disease progression (to end of main observation period) was reduced with initial triple versus initial double therapy (hazard ratio: 0.59; 95% confidence interval: 0.32-1.09). Most common adverse events with initial triple therapy included headache, diarrhea, and nausea. By the end of the main observation period, 2 patients in the initial triple and 9 in the initial double therapy groups had died. CONCLUSIONS: In patients with newly diagnosed PAH, both treatment strategies markedly reduced PVR by week 26, with no significant difference between groups (primary endpoint not met). Exploratory analyses suggested a possible signal for improved long-term outcomes with initial triple versus initial double oral therapy.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Chin KM, Sitbon O, Doelberg M, et al. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2021. PMID: 34593120. doi:10.1016/j.jacc.2021.07.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。